Does chronic fatigue syndrome predispose to non-Hodgkin's lymphoma? 1992

P H Levine, and D Peterson, and F L McNamee, and K O'Brien, and G Gridley, and M Hagerty, and J Brady, and T Fears, and M Atherton, and R Hoover
Epidemiology and Biostatistics Program, National Cancer Institute, NIH, Bethesda, Maryland 20892.

Chronic fatigue syndrome, an illness that frequently is associated with abnormalities of cellular immunity, has been reported anecdotally to be associated with an increased incidence of lymphoid hyperplasia and malignancy. This report describes an initial analysis of population-based cancer incidence data in Nevada, focusing on the patterns of non-Hodgkin's lymphoma prior to and subsequent to well described, documented outbreaks of chronic fatigue syndrome during 1984-1986. In a study of time trends in four age groups, the observed time trends were consistent with the national trends reported in the Surveillance, Epidemiology, and End Results Program. No statistically significant increase attributable to the chronic fatigue syndrome outbreak was identified at the state level. Additional studies are in progress analyzing the data at the country level, reviewing patterns in other malignancies, and continuing to monitor the cancer patterns over subsequent years.

UI MeSH Term Description Entries
D008228 Lymphoma, Non-Hodgkin Any of a group of malignant tumors of lymphoid tissue that differ from HODGKIN DISEASE, being more heterogeneous with respect to malignant cell lineage, clinical course, prognosis, and therapy. The only common feature among these tumors is the absence of giant REED-STERNBERG CELLS, a characteristic of Hodgkin's disease. Non-Hodgkin Lymphoma,Diffuse Mixed Small and Large Cell Lymphoma,Diffuse Mixed-Cell Lymphoma,Diffuse Small Cleaved-Cell Lymphoma,Diffuse Undifferentiated Lymphoma,Lymphatic Sarcoma,Lymphoma, Atypical Diffuse Small Lymphoid,Lymphoma, Diffuse,Lymphoma, Diffuse, Mixed Lymphocytic-Histiocytic,Lymphoma, High-Grade,Lymphoma, Intermediate-Grade,Lymphoma, Low-Grade,Lymphoma, Mixed,Lymphoma, Mixed Cell, Diffuse,Lymphoma, Mixed Lymphocytic-Histiocytic,Lymphoma, Mixed Small and Large Cell, Diffuse,Lymphoma, Mixed-Cell,Lymphoma, Mixed-Cell, Diffuse,Lymphoma, Non-Hodgkin's,Lymphoma, Non-Hodgkin, Familial,Lymphoma, Non-Hodgkins,Lymphoma, Nonhodgkin's,Lymphoma, Nonhodgkins,Lymphoma, Pleomorphic,Lymphoma, Small Cleaved Cell, Diffuse,Lymphoma, Small Cleaved-Cell, Diffuse,Lymphoma, Small Non-Cleaved-Cell,Lymphoma, Small Noncleaved-Cell,Lymphoma, Small and Large Cleaved-Cell, Diffuse,Lymphoma, Undifferentiated,Lymphoma, Undifferentiated, Diffuse,Lymphosarcoma,Mixed Small and Large Cell Lymphoma, Diffuse,Mixed-Cell Lymphoma,Mixed-Cell Lymphoma, Diffuse,Non-Hodgkin's Lymphoma,Reticulosarcoma,Reticulum Cell Sarcoma,Reticulum-Cell Sarcoma,Sarcoma, Lymphatic,Sarcoma, Reticulum-Cell,Small Cleaved-Cell Lymphoma, Diffuse,Small Non-Cleaved-Cell Lymphoma,Small Noncleaved-Cell Lymphoma,Undifferentiated Lymphoma,Diffuse Lymphoma,Diffuse Lymphomas,Diffuse Mixed Cell Lymphoma,Diffuse Mixed-Cell Lymphomas,Diffuse Small Cleaved Cell Lymphoma,Diffuse Undifferentiated Lymphomas,High-Grade Lymphoma,High-Grade Lymphomas,Intermediate-Grade Lymphoma,Intermediate-Grade Lymphomas,Low-Grade Lymphoma,Low-Grade Lymphomas,Lymphatic Sarcomas,Lymphocytic-Histiocytic Lymphoma, Mixed,Lymphocytic-Histiocytic Lymphomas, Mixed,Lymphoma, Diffuse Mixed-Cell,Lymphoma, Diffuse Undifferentiated,Lymphoma, High Grade,Lymphoma, Intermediate Grade,Lymphoma, Low Grade,Lymphoma, Mixed Cell,Lymphoma, Mixed Lymphocytic Histiocytic,Lymphoma, Non Hodgkin,Lymphoma, Non Hodgkin's,Lymphoma, Non Hodgkins,Lymphoma, Nonhodgkin,Lymphoma, Small Non Cleaved Cell,Lymphoma, Small Noncleaved Cell,Lymphosarcomas,Mixed Cell Lymphoma,Mixed Cell Lymphoma, Diffuse,Mixed Lymphocytic-Histiocytic Lymphoma,Mixed Lymphocytic-Histiocytic Lymphomas,Mixed Lymphoma,Mixed Lymphomas,Mixed-Cell Lymphomas,Non Hodgkin Lymphoma,Non Hodgkin's Lymphoma,Non-Cleaved-Cell Lymphoma, Small,Non-Hodgkins Lymphoma,Noncleaved-Cell Lymphoma, Small,Nonhodgkin's Lymphoma,Nonhodgkins Lymphoma,Pleomorphic Lymphoma,Pleomorphic Lymphomas,Reticulosarcomas,Reticulum Cell Sarcomas,Reticulum-Cell Sarcomas,Sarcoma, Reticulum Cell,Small Cleaved Cell Lymphoma, Diffuse,Small Non Cleaved Cell Lymphoma,Small Non-Cleaved-Cell Lymphomas,Small Noncleaved Cell Lymphoma,Small Noncleaved-Cell Lymphomas,Undifferentiated Lymphoma, Diffuse,Undifferentiated Lymphomas
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D009505 Nevada State bounded on the north by Oregon and Idaho, on the east by Utah, on the south and west by California.
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000293 Adolescent A person 13 to 18 years of age. Adolescence,Youth,Adolescents,Adolescents, Female,Adolescents, Male,Teenagers,Teens,Adolescent, Female,Adolescent, Male,Female Adolescent,Female Adolescents,Male Adolescent,Male Adolescents,Teen,Teenager,Youths
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D000367 Age Factors Age as a constituent element or influence contributing to the production of a result. It may be applicable to the cause or the effect of a circumstance. It is used with human or animal concepts but should be differentiated from AGING, a physiological process, and TIME FACTORS which refers only to the passage of time. Age Reporting,Age Factor,Factor, Age,Factors, Age
D000368 Aged A person 65 years of age or older. For a person older than 79 years, AGED, 80 AND OVER is available. Elderly
D015673 Fatigue Syndrome, Chronic A syndrome characterized by persistent or recurrent fatigue, diffuse musculoskeletal pain, sleep disturbances, and subjective cognitive impairment of 6 months duration or longer. Symptoms are not caused by ongoing exertion; are not relieved by rest; and result in a substantial reduction of previous levels of occupational, educational, social, or personal activities. Minor alterations of immune, neuroendocrine, and autonomic function may be associated with this syndrome. There is also considerable overlap between this condition and FIBROMYALGIA. (From Semin Neurol 1998;18(2):237-42; Ann Intern Med 1994 Dec 15;121(12): 953-9) Chronic Fatigue Syndrome,Encephalomyelitis, Myalgic,Infectious Mononucleosis-Like Syndrome, Chronic,Postviral Fatigue Syndrome,Chronic Fatigue Disorder,Chronic Fatigue and Immune Dysfunction Syndrome,Chronic Fatigue-Fibromyalgia Syndrome,Myalgic Encephalomyelitis,Royal Free Disease,Systemic Exertion Intolerance Disease,Chronic Fatigue Disorders,Chronic Fatigue Fibromyalgia Syndrome,Chronic Fatigue Syndromes,Chronic Fatigue-Fibromyalgia Syndromes,Fatigue Disorder, Chronic,Fatigue Syndrome, Postviral,Fatigue Syndromes, Chronic,Fatigue-Fibromyalgia Syndrome, Chronic,Fatigue-Fibromyalgia Syndromes, Chronic,Infectious Mononucleosis Like Syndrome, Chronic,Postviral Fatigue Syndromes,Syndrome, Postviral Fatigue
D015994 Incidence The number of new cases of a given disease during a given period in a specified population. It also is used for the rate at which new events occur in a defined population. It is differentiated from PREVALENCE, which refers to all cases in the population at a given time. Attack Rate,Cumulative Incidence,Incidence Proportion,Incidence Rate,Person-time Rate,Secondary Attack Rate,Attack Rate, Secondary,Attack Rates,Cumulative Incidences,Incidence Proportions,Incidence Rates,Incidence, Cumulative,Incidences,Person time Rate,Person-time Rates,Proportion, Incidence,Rate, Attack,Rate, Incidence,Rate, Person-time,Rate, Secondary Attack,Secondary Attack Rates

Related Publications

P H Levine, and D Peterson, and F L McNamee, and K O'Brien, and G Gridley, and M Hagerty, and J Brady, and T Fears, and M Atherton, and R Hoover
April 1995, AIDS (London, England),
P H Levine, and D Peterson, and F L McNamee, and K O'Brien, and G Gridley, and M Hagerty, and J Brady, and T Fears, and M Atherton, and R Hoover
January 1995, Archivos de bronconeumologia,
P H Levine, and D Peterson, and F L McNamee, and K O'Brien, and G Gridley, and M Hagerty, and J Brady, and T Fears, and M Atherton, and R Hoover
February 2020, Irish medical journal,
P H Levine, and D Peterson, and F L McNamee, and K O'Brien, and G Gridley, and M Hagerty, and J Brady, and T Fears, and M Atherton, and R Hoover
February 1999, Journal of the Royal Society of Medicine,
P H Levine, and D Peterson, and F L McNamee, and K O'Brien, and G Gridley, and M Hagerty, and J Brady, and T Fears, and M Atherton, and R Hoover
January 1994, Pediatric hematology and oncology,
P H Levine, and D Peterson, and F L McNamee, and K O'Brien, and G Gridley, and M Hagerty, and J Brady, and T Fears, and M Atherton, and R Hoover
May 1977, Southern medical journal,
P H Levine, and D Peterson, and F L McNamee, and K O'Brien, and G Gridley, and M Hagerty, and J Brady, and T Fears, and M Atherton, and R Hoover
June 1990, Seminars in oncology,
P H Levine, and D Peterson, and F L McNamee, and K O'Brien, and G Gridley, and M Hagerty, and J Brady, and T Fears, and M Atherton, and R Hoover
October 1997, Respiratory medicine,
P H Levine, and D Peterson, and F L McNamee, and K O'Brien, and G Gridley, and M Hagerty, and J Brady, and T Fears, and M Atherton, and R Hoover
July 1989, The Journal of the Association of Physicians of India,
P H Levine, and D Peterson, and F L McNamee, and K O'Brien, and G Gridley, and M Hagerty, and J Brady, and T Fears, and M Atherton, and R Hoover
May 1990, Medicina clinica,
Copied contents to your clipboard!